Diatide and Nycomed withdraw European blood clot test application
This article was originally published in Clinica
Executive Summary
Diatide and Nycomed Amersham have temporarily withdrawn a European Marketing Authorisation Application (MAA) for AcuTect, a radiopharmaceutical used to detect potentially fatal blood clots in the legs.